The firm, Proteomedix Frontiers, has developed SRM-MS assays for more than 400 proteins that could be important to drug development efforts. It plans to offer them to pharma researchers both as kits and through agreements with contract research organizations.
Recent collaboration agreements between the company and researchers at the Moffitt Cancer Center and the Buck Institute for Research on Aging will further its "intention of building a portfolio of oncology-related assays using selected-reaction monitoring," said an official.
The work suggests that glycosylation may play a key role in the proteolytic processing of the amyloid precursor protein, implicating it in the generation of Aβ peptide fragments like Aβ1-42 that have been linked to Alzheimer's, said one of the researchers.
The work is part of the European Union's £6.99 million DENAMIC research project, which aims to develop tools for monitoring the neurotoxic effects of environmental pollutants on the cognitive skills and development of children.